Kezar Life Sciences Taps Noreen Roth Henig as Chief Medical Officer

Kezar Life Sciences (NASDAQ: [[ticker:KZR]]) has appointed Noreen Roth Henig to serve as its chief medical officer, the same role she held most recently at Breath Therapeutics. Breath was acquired by Zambon last year for €140 million up front. Henig’s experience also includes roles at ProQR Therapeutics and Gilead Sciences (NASDAQ: [[ticker:GILD]]). South San Francisco-based Kezar, which went public in 2018, is developing treatments for autoimmune diseases and cancer. Its most advanced program, KZR-616, is being evaluated in three separate Phase 2 studies spanning five autoimmune conditions.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan